Showing 1-11 of 11 results for "106-49-0"
John Fr Robertson et al.
The Lancet. Oncology, 14(3), 228-235 (2013-02-19)
Insulin-like growth factors (IGF-1 and IGF-2) bind to the IGF-1 receptor (IGF-1R), increasing cell proliferation and survival. Ganitumab is a monoclonal IgG1 antibody that blocks IGF-1R. We tested the efficacy and safety of adding ganitumab to endocrine treatment for patients...
Shuju Wang et al.
Se pu = Chinese journal of chromatography, 25(2), 226-229 (2007-06-22)
A method for the simultaneous determination of captan and folpet pesticide residues in apples was developed by solid-phase extraction and high performance liquid chromatography. The sample was extracted with acetonitrile and cleaned-up by a mixture of homemade sorbent and silica...
K M Abdo et al.
Fundamental and applied toxicology : official journal of the Society of Toxicology, 2(5), 201-210 (1982-09-01)
Diets containing 0.1 or 0.3% 2-biphenylamine hydrochloride were fed to groups of 50 Fischer 344 rats and 50 B6C3F1 mice of each sex for 104-106 weeks. Mean body weights of high-dose rats of both sexes and of low-dose male rats...
Jin-Shing Chen et al.
Lancet (London, England), 381(9874), 1277-1282 (2013-03-16)
Simple aspiration and drainage is a standard initial treatment for primary spontaneous pneumothorax, but the rate of pneumothorax recurrence is substantial. We investigated whether additional minocycline pleurodesis after simple aspiration and drainage reduces the rate of recurrence. In our open-label...
Alex Lin et al.
Journal of neuropathology and experimental neurology, 71(1), 66-72 (2011-12-14)
Recent studies highlight the importance of BRAF alterations resulting in mitogen activated protein kinase (MAK/ERK) pathway activation in low-grade CNS tumors. We studied 106 low-grade CNS neoplasms in a cohort of primarily pediatric patients to identify the prevalence and clinicopathologic...
Oliwia Anna Segiet et al.
Anatolian journal of cardiology, 21(6), 305-313 (2019-05-31)
Despite several improvements in the management of heart failure (HF), it is still an incurable and a progressive disease. Several trials demonstrated that the process of inflammation may be responsible for initiation and progression of HF. The aim of the...
B I Hudson et al.
Diabetes, 50(6), 1505-1511 (2001-05-26)
Interactions between advanced glycation end products (AGEs) and the receptor for AGE (RAGE) are implicated in the vascular complications in diabetes. We have identified eight novel polymorphisms, of which the -1420 (GGT)n, -1393 G/T, -1390 G/T, and -1202 G/A were...
Clemens Wittenbecher et al.
The American journal of clinical nutrition, 101(6), 1241-1250 (2015-05-08)
Habitual red meat consumption was consistently related to a higher risk of type 2 diabetes in observational studies. Potentially underlying mechanisms are unclear. This study aimed to identify blood metabolites that possibly relate red meat consumption to the occurrence of...
Niels Wcj van de Donk et al.
The Lancet. Haematology, 5(10), e479-e492 (2018-10-07)
In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and maintenance regimens (in conjunction with high-dose melphalan and autologous stem cell transplantation [auto-SCT]) after a median of 52 months of...
Ira M Jacobson et al.
Lancet (London, England), 384(9941), 403-413 (2014-06-08)
Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained virological response (SVR) in treatment-naive and treatment-experienced patients infected with hepatitis C virus (HCV) genotype 1, the regimens...
Rosario Pivonello et al.
The lancet. Diabetes & endocrinology, 8(9), 748-761 (2020-07-31)
Cushing's disease is a rare endocrine disorder characterised by cortisol overproduction with severe complications. Therapies for cortisol reduction are often necessary. Here we report the outcomes from the pivotal phase III study of osilodrostat (a potent oral inhibitor of cytochrome...

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.